Atecegatran

• Description :

  Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders[1].

• Product Name Alternative :

  AR-H067637

• UNSPSC :

  12352005

• Target :

  Thrombin

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/atecegatran.html

• Smiles :

  O=C([C@H](O)C1=CC(OC(F)F)=CC(Cl)=C1)N(CC2)[C@@H]2C(NCC3=CC=C(C=C3)C(N)=N)=O

• Molecular Formula :

  C21H21ClF2N4O4

• Molecular Weight :

  466.87

• References & Citations :

  [1]Deinum J, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009 Jun;101 (6) :1051-9.|[2]Deinum J, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009 Jun;101 (6) :1051-9.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [433937-74-7]